Immune‐Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis

Documenti analoghi

• A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database
  di: Boyi Liu, et al.
  Pubblicazione: (2026)
• Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System
  di: Shaimaa Elshafie, et al.
  Pubblicazione: (2024)
• Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival
  di: Yin Leung, et al.
  Pubblicazione: (2025)
• Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
  di: Wenke Li, et al.
  Pubblicazione: (2025)
• A Real‐Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune‐Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab
  di: Atsuto Mouri, et al.
  Pubblicazione: (2025)